OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Oncology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data	1180
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?	393
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	357
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	336
Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence	291
Information Blocking and Oncology	288
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	268
High-risk Medulloblastoma—Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity	252
JAMA Oncology	239
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer	232
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?	231
Redefining Attribution From Patient to Health System—How the Notion of “Mistrust” Places Blame on Black Patients—Reply	229
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	221
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	217
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	201
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	194
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	191
Stargazers	184
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	177
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	174
Errors in Key Points and Abstract	171
Error in Text	170
Coffee Consumption and Colorectal Cancer Prognosis—Reply	168
The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening	164
Piercing the Fog	162

Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	157
Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors	155
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	152
The Multidisciplinary Cancer Conference	144
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	139
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years	138
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades	133
Overall Survival in the CAIRO5 Clinical Trial	128
Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer	128
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	123
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non–Small-Cell Lung Cancer	123
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy	121
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	121
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	114
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	109
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors	109
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	108
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	108
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	106
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant	106
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	101
Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply	101
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	101
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?	101
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size	99
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?	96
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	94
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply	93
Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography—The IP1-PROSTAGRAM Study—Reply	93
Coding Errors in Study of Eligibility for Lung Cancer Screening	91
Is Colorectal Cancer Screening Absolutely Beneficial for Older Adults?	91
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	91
Asymptomatic Purpuric Eruption on the Scalp of a Middle-aged Man	90
Industry Payments to Medical Oncologists	89
Errors in Reported Outcomes and Table	86
Results of the TARGET-TP Randomized Clinical Trial	84
The SOUND Randomized Clinical Trial Results	83
Variability in COVID-19 Vaccine Response Among People With Cancer	83
The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval	81
Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia—Moving From Evidence to Practice	79
Trauma	79
JAMA Oncology	78
An Atypical Rash on the Chest	78
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation	77
Immunotherapy Before Chemoradiotherapy—More Is Better?	77
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	76
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients	76
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma	75
Accelerated Approval Is Not Conditional Approval	74
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	74

Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer	73
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy	72
Clinical Trial Diversity—Will We Know It When We See It?	70
Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China	69
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	69
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Don	69
Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer	68
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	68
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	68
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma	67
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	67
Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic	67
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	67
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy	67
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	67
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia	67
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	67
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer	66
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer	66
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set	66
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy	65
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis	65
“Benign”	65
Last Christmas—Counseling Patients in the Era of COVID-19	64
Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?	63
Change of Article Status to Open Access	63
JAMA Oncology	63
Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence—Reply	63
Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?—Reply	63
Pragmatic Solutions to Counteract the Regressive Effects of the COVID-19 Pandemic for Women in Academic Oncology	62
Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria	62
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	61
Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia	60
Self-reported Transportation Barriers to Health Care Among US Cancer Survivors	60
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials	60
Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer	60
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer	60
Global Stage Distribution of Breast Cancer at Diagnosis	60
On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer	59
Exposure Histories and Cancer Risk—What Can We Learn?	59
JAMA Oncology Peer Reviewers in 2021	58
Baseline Evaluation of Cancer Mortality in US States that Expanded Medicaid vs Nonexpansion States	58
Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven’t Found What We’re Looking For	57
Role of Patient-Reported Outcome Measures in the Inpatient Setting—Reply	57
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes	57
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	57
“You’ve Got Mail”—Receiving Bad News Through a Patient Portal	57
Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication	57
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial—Reply	57
The ORATOR Trials Have Spoken—Where Do We Go From Here?	56
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL	56
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer	56
Analysis of Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Using Pooled Trial Data Matched by Propensity Score	56
The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers	56
JAMA Oncology	54
Endocrine Society Hypercalcemia of Malignancy Guidelines	52
Characterizing Lung Cancer in Li-Fraumeni Syndrome	52
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer	52
Sunsets	51
Luminal and Basal Subtypes of Metastatic Prostate Cancer	51
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma	51
JAMA Oncology	51
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer	51
Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens	51
Infiltrating	51
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma	51
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer—Reply	50
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters	50
Single-Dose Radiotherapy for Prostate Cancer—Lessons Learned From Single-Fraction High-Dose-Rate Brachytherapy	50
Pancytopenia in a Patient With Metastatic Well-Differentiated Neuroendocrine Tumor After Peptide Receptor Radionuclide Therapy	49
Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database	48
Should Thiotepa-Based Regimens Be the New Transplant Conditioning Strategy for Primary Central Nervous System Lymphoma?	48
JAMA Oncology	48
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer	48
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer	48
Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer	47
Exploration of Clinician Perspectives on Multidisciplinary Tumor Board Function Beyond Clinical Decision-making	47
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer	46
Oral Mucosal Pigmentation in a Patient With Mycosis Fungoides	46
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation	45

Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer—Reply	45
MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas	44
Managing Cancer Pain in Patients With Opioid Use Disorder or Nonmedical Opioid Use	44
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction—Reply	43
Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge	43
Management of Down Syndrome–Associated Leukemias	43
Valid Analysis of Brain-Specific Progression-Free Survival	43
Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease	43
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma	42
Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma	42
The Oncology Industrial Complex—Community Oncology Must Be Given a Seat at the Table—Reply	42
Association of Patient-Reported Outcomes With Subsequent Nonfatal Self-injury After a New Cancer Diagnosis	42
Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015	42
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion	41
Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors	41
COVID-19 and Cancer	41
Errors in Figures 2 and 3	41
Personalized Radiation Therapy—Spurning the “One Size Fits All” Approach	41
Artificial Intelligence—From Starting Pilots to Scalable Privilege	41
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer	41
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy	40
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer	40
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis	40
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer	40
JAMA Oncology	40
Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer	40
Change of Article Status to Open Access	39
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations	38
Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objective—Reply	38
Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice	38
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker	38
Scattered Painful Papulonodules in an Older Woman	38
The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies	37
The SOUND Randomized Clinical Trial Results—Reply	37
Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases	37
Error in Figure	37
Two Hands, One Journey	37
Somebody Else’s Palms	37
Dog Aloisanov Helped Diagnose My Cancer	37
Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?—Reply	37
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies	36
Error in Figure 1	36
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction	36
Immune-Related Adverse Events and Efficacy—The More It Hurts, the Better It Works?	36
Locally Advanced Relapse May Not Be Equal to Stage 3 Non–Small Cell Lung Cancer	36
Errors in Figure 3	36
Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma—A New Standard of Care?—Reply	36
Cervical Cancer Incidence in the US-Affiliated Pacific Islands	36
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer	36
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer	35
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma	35
Unintended Consequences of Patient Portal Access	35
Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use	35
Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy	34
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer	34
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients	34
Financial Toxicity Among Asian American Cancer Survivors	34
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021	34
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer	34
JAMA Oncology	33
Change to Open Access Status	33
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma	33
Error in Affiliation and Address	33
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases	33
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply	33
USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence	33
Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor–Mutant Lung Cancer	33
PARP Inhibitors for Breast Cancer Treatment	33
An Intramedullary Enigma	33
The Urgent Need for Affordability Curricula at US Medical Schools	33
A Case of Multiple Hemorrhagic Friable Nodules	33
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer	32
Reexamining Social Determinants of Health Data Collection in the COVID-19 Era	32
Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions	32
Equity and the JAMA Network	32
Error in Author Surname	32
Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer	32
Change to Open Access	31
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer	31
Blood Clots, or Thrombosis, in Patients With Cancer	31
Is 2045 Optimistic?—Concerns Regarding Rising Vaccine Hesitancy—Reply	31
The Abiraterone Dosing Chess Match With Johnson & Johnson—Back in Check	31
Error in Abstract	31
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck—Reply	30
Error in the Additional Contributions Section	30
Patient Harassment of Medical Trainees	30
Government Funding for the Development of Enzalutamide	30
Racial Disparities and Survival Outcomes in Breast Cancer—Reply	30
Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens	29
Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?—Reply	29
Implementing Smoking Cessation Interventions for Tobacco Users Within Oncology Settings	29
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors	29
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer	29
SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents	29
Charting the Path to Systemic Therapy De-escalation—Oligometastatic Kidney Cancer as a Paradigm	29